|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Constitutional mutations of TP53AIP1 had previously been involved in susceptibility to prostate cancer.
|
29359367 |
2018 |
|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that loss-of-function variants in p53AIP1 associated with the risk of sporadic prostate cancer and further support the concept that the genetic defects in the DNA damage-response genes play an important role in the development of prostate cancer.
|
17079449 |
2006 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Constitutional mutations of TP53AIP1 had previously been involved in susceptibility to prostate cancer.
|
29359367 |
2018 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that loss-of-function variants in p53AIP1 associated with the risk of sporadic prostate cancer and further support the concept that the genetic defects in the DNA damage-response genes play an important role in the development of prostate cancer.
|
17079449 |
2006 |
|
Cutaneous Melanoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In all patients, TP53AIP1 truncating variants were strongly associated with CMM risk (two-sided Fisher exact test = 0.004, OR = 3.3[1.3-8.5]).
|
29359367 |
2018 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Finally, adenovirus-mediated introduction of p53AIP1 suppressed tumor growth in vivo.
|
14720333 |
2004 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In addition, two of six tumors carrying the truncating variants were associated with loss of heterozygosity of the wild-type alleles, suggesting that p53AIP1 may act as a tumor suppressor.
|
17079449 |
2006 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In 20 of the 30 cell lines, p53AIP1-induced apoptosis was observed, and in 12 of these p53AIP1-sensitive cancer cell lines, the apoptotic effects of p53AIP1 were greater than those of p53 itself.
|
14720333 |
2004 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The present study determined that miR‑505‑5p functions as an oncogene, promoting lung cancer cell proliferation and inhibiting cancer cell apoptosis via the targeting of tumor protein P53‑regulated apoptosis‑inducing protein 1 (TP53AIP1).
|
30864684 |
2019 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
The large sample size of the combined cohort rejects a high-risk effect greater than 2.2 and indicates a limited role of TP53AIP1 in prostate cancer predisposition.
|
22457820 |
2012 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The large sample size of the combined cohort rejects a high-risk effect greater than 2.2 and indicates a limited role of TP53AIP1 in prostate cancer predisposition.
|
22457820 |
2012 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
The present study determined that miR‑505‑5p functions as an oncogene, promoting lung cancer cell proliferation and inhibiting cancer cell apoptosis via the targeting of tumor protein P53‑regulated apoptosis‑inducing protein 1 (TP53AIP1).
|
30864684 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
In 20 of the 30 cell lines, p53AIP1-induced apoptosis was observed, and in 12 of these p53AIP1-sensitive cancer cell lines, the apoptotic effects of p53AIP1 were greater than those of p53 itself.
|
14720333 |
2004 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These data suggest that the p53AIP1 gene is important for non-small cell lung cancer progression and may be a possible prognostic marker.
|
17851056 |
2008 |
|
Alexithymia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
From our analysis, variants in the genes ABCB4, TP53AIP1, ARHGAP32 and TMEM88B were identified linked to the alexithymia phenotype.
|
25882097 |
2015 |
|
Lung Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
p53AIP1 expression can be a prognostic marker in non-small cell lung cancer.
|
17851056 |
2008 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
The mechanism of TP53AIP1 inhibition of proliferation and growth of breast cancer cells includes cell cycle arrest, apoptosis promotion (<i>p</i> < 0.01), promotion of the expression of cleaved-caspase-3 (<i>p</i> < 0.01), cleaved-caspase-9 (<i>p</i> < 0.01), B cell lymphoma/leukemia-2 (Bcl-2)-associated X protein, and p53 (<i>p</i> < 0.01), and the inhibition of Bcl-2, Ki67, and PI3K/Akt pathways (<i>p</i> < 0.01).
|
31281721 |
2019 |
|
Carcinogenesis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
H. pylori infection induces gastric mucosal inflammation and DNA damage of epithelial cells, which associate with gastric carcinogenesis. p53AIP1 is expressed after DNA damage and induces apoptosis in human cell lines.
|
18277906 |
2008 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Six of the TP53AIP1 levels in the tumor and adjacent non-tumor tissues randomly selected from 38 breast cancer patients were determined.
|
31281721 |
2019 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
DX reduced DeltaNp73alpha protein expression, without affecting its nuclear localization. p53, p21, Bax and p53AIP1 protein expression increased and Bcl-2 decreased in HCT116 clone derived tumors 24 hr after DX exposure, independently of the presence of DeltaNp73alpha.
|
17096333 |
2007 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
The study also showed alterations in p53 protein-associated genes, among these increased gene expression of p53, up-regulation of Reprimo or candidate mediator of the p53-dependent G2-arrest, down-regulation of p53-regulated apoptosis-inducing protein 1 (p53AIP1), decreased expression of tumor protein inducible nuclear protein 1 (p53DINP1), and down-regulation of Mdm4 (MDMX).
|
17611651 |
2007 |
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Combination treatment and PEG-IFN monotherapy also significantly elevated the p53 protein and mRNA levels in the tumour but only combination treatment increased the degree of p53 phosphorylation at serine46 and induced p53-regulated apoptosis-inducing protein 1 (p53AIP1) expression.
|
17971768 |
2007 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The degree of correlation between TP53AIP1 expression and overall survival in patients with breast cancer was obtained from the online The Cancer Genome Atlas database.
|
31281721 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The degree of correlation between TP53AIP1 expression and overall survival in patients with breast cancer was obtained from the online The Cancer Genome Atlas database.
|
31281721 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that the combination of p53AIP1 and survivin gene expression may be a powerful tool to stratify subgroups with better or worse prognosis from the variable non-small cell lung cancer population.
|
19228369 |
2009 |